{"transactions":[{"id":727622,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2026-06-24T13:57:31.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":34.99,"expiration_date":"2036-06-22","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-26-021509","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021509/rdgdoc.xml","form_type":"4"}},{"id":919253,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:04:12.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":263033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":263033,"derivative":{"underlying":"Common Stock","underlying_shares":263033},"source":{"system":"sec-edgar","filing":"0001296549-26-000002","document":"wk-form4_1770242650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000129654926000002/wk-form4_1770242650.xml","form_type":"4"}},{"id":919252,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:04:12.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":929913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":929913,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":929913},"source":{"system":"sec-edgar","filing":"0001296549-26-000002","document":"wk-form4_1770242650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000129654926000002/wk-form4_1770242650.xml","form_type":"4"}},{"id":1039877,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":30667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1262},"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039876,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":13302666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":547648},"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039875,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":767,"price":15,"value":11505.0,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":2029,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039874,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":332566,"price":15,"value":4988490.0,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":880214,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039873,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":1262,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":1262,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1039872,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":1,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":2,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":3,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35650,"kind":"person","name":"Belldegrun Arie","position":4,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75350,"kind":"organization","name":"Vida Ventures Management Co. LLC","position":5,"cik":"0001905615","reported_name":"Vida Ventures Management Co. LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T19:46:23.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":547648,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an \"Investment Committee Member\" and such committee, the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":547648,"source":{"system":"sec-edgar","filing":"0001193125-25-204935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000119312525204935/ownership.xml","form_type":"4"}},{"id":1054530,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2025-08-27T20:36:19.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":19.5,"expiration_date":"2035-08-26","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-25-027877","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925027877/rdgdoc.xml","form_type":"4"}},{"id":1104867,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1104866,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1104865,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1104864,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1104863,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":679575,"price":0.57,"value":387357.75,"ownership":{"direct":false,"nature":"By Bellco Legacy II Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1104862,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:41.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":2765314,"price":0.57,"value":1576228.98,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017834","document":"form4-06202025_040628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588925017834/form4-06202025_040628.xml","form_type":"4"}},{"id":1292933,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:11:46.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":1307927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1307927,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":1307927},"source":{"system":"sec-edgar","filing":"0001737287-25-000005","document":"wk-form4_1738113099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728725000005/wk-form4_1738113099.xml","form_type":"4"}},{"id":1292932,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-29T01:11:46.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":369957,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2236816,"source":{"system":"sec-edgar","filing":"0001737287-25-000005","document":"wk-form4_1738113099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728725000005/wk-form4_1738113099.xml","form_type":"4"}},{"id":1437868,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2024-08-08T13:11:37.000Z","date":"2024-08-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":15.16,"expiration_date":"2034-08-06","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-24-025299","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774924025299/rdgdoc.xml","form_type":"4"}},{"id":1468668,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T20:31:22.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-24-018230","document":"form4-06262024_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000141588924018230/form4-06262024_080619.xml","form_type":"4"}},{"id":1478820,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option","published_at":"2024-06-14T20:26:13.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":571428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."}],"balance_after":571428,"derivative":{"exercise_price":0.462,"expiration_date":"2034-06-13","underlying":"Class A Common Stock","underlying_shares":571428},"source":{"system":"sec-edgar","filing":"0001127602-24-018717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760224018717/form4.xml","form_type":"4"}},{"id":1478819,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-14T20:26:13.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":432900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date."}],"balance_after":432900,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":432900},"source":{"system":"sec-edgar","filing":"0001127602-24-018717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760224018717/form4.xml","form_type":"4"}},{"id":1478818,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-14T20:26:13.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":false,"shares":105263,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":105263},"source":{"system":"sec-edgar","filing":"0001127602-24-018717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760224018717/form4.xml","form_type":"4"}},{"id":1478817,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2024-06-14T20:26:13.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":true,"shares":105263,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":194925,"source":{"system":"sec-edgar","filing":"0001127602-24-018717","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760224018717/form4.xml","form_type":"4"}},{"id":1508828,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T01:33:32.000Z","date":"2024-05-16","kind":"purchase","planned":false,"acquired":true,"shares":1724137,"price":2.9,"value":4999997.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Consists of 1,720,172 shares of common stock acquired by Vida Ventures III, L.P. and 3,965 shares of common stock acquired by Vida Ventures III A, L.P. from Goldman Sachs (the Underwriter) in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1724137,"source":{"system":"sec-edgar","filing":"0001737287-24-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728724000042/primary_doc.xml","form_type":"4"}},{"id":1508827,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T01:33:32.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":344828,"price":2.9,"value":1000001.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the \"Issuer\") in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun."}],"balance_after":539867,"source":{"system":"sec-edgar","filing":"0001737287-24-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728724000042/primary_doc.xml","form_type":"4"}},{"id":1665025,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-31T22:46:40.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":749398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":749398,"derivative":{"exercise_price":3.2,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":749398},"source":{"system":"sec-edgar","filing":"0001593968-24-000194","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000159396824000194/primary_01.xml","form_type":"4"}},{"id":1665024,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-31T22:46:40.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":211973,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1866859,"source":{"system":"sec-edgar","filing":"0001593968-24-000194","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000159396824000194/primary_01.xml","form_type":"4"}},{"id":1784657,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2023-09-08T19:43:29.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":16.85,"expiration_date":"2033-09-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-23-025486","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923025486/rdgdoc.xml","form_type":"4"}},{"id":1844115,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T20:08:03.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-039683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919123039683/doc4.xml","form_type":"4"}},{"id":1847678,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option","published_at":"2023-06-21T21:03:27.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":139860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."}],"balance_after":139860,"derivative":{"exercise_price":1.9,"expiration_date":"2033-06-16","underlying":"Class A Common Stock","underlying_shares":139860},"source":{"system":"sec-edgar","filing":"0001127602-23-019165","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760223019165/form4.xml","form_type":"4"}},{"id":1847677,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-21T21:03:27.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":105263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."}],"balance_after":105263,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":105263},"source":{"system":"sec-edgar","filing":"0001127602-23-019165","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000112760223019165/form4.xml","form_type":"4"}},{"id":1939032,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-25T00:14:49.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":994800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":994800,"derivative":{"exercise_price":5.04,"expiration_date":"2033-03-22","underlying":"Common Stock","underlying_shares":994800},"source":{"system":"sec-edgar","filing":"0001593968-23-000523","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000159396823000523/primary_01.xml","form_type":"4"}},{"id":1939031,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-03-25T00:14:49.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":1282976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 986,905 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period."}],"balance_after":1654886,"source":{"system":"sec-edgar","filing":"0001593968-23-000523","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000159396823000523/primary_01.xml","form_type":"4"}},{"id":2157342,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-09-16T19:13:17.000Z","date":"2022-09-14","kind":"exercise","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2019-10-07","expiration_date":"2022-10-07","underlying":"Ordinary Shares","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-22-022616","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922022616/rdgdoc.xml","form_type":"4"}},{"id":2157341,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-09-16T19:13:17.000Z","date":"2022-09-14","kind":"exercise","acquired":true,"shares":160000,"price":5,"value":800000.0,"ownership":{"direct":true},"balance_after":408693,"source":{"system":"sec-edgar","filing":"0001437749-22-022616","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922022616/rdgdoc.xml","form_type":"4"}},{"id":2167560,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-09-02T15:40:33.000Z","date":"2022-08-31","kind":"exercise","acquired":false,"shares":3241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2015-09-01","expiration_date":"2022-09-01","underlying":"Ordinary Shares","underlying_shares":3241},"source":{"system":"sec-edgar","filing":"0001437749-22-021777","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922021777/rdgdoc.xml","form_type":"4"}},{"id":2167559,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-09-02T15:40:33.000Z","date":"2022-08-31","kind":"exercise","acquired":true,"shares":3241,"price":5,"value":16205.0,"ownership":{"direct":true},"balance_after":248693,"source":{"system":"sec-edgar","filing":"0001437749-22-021777","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922021777/rdgdoc.xml","form_type":"4"}},{"id":2219292,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T20:06:22.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-22-039774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919122039774/doc4.xml","form_type":"4"}},{"id":2233916,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-14T01:13:18.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":108516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date."}],"balance_after":108516,"derivative":{"exercise_price":2.82,"expiration_date":"2032-06-10","underlying":"Class A Common Stock","underlying_shares":108516},"source":{"system":"sec-edgar","filing":"0000899243-22-022286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000089924322022286/doc4.xml","form_type":"4"}},{"id":2233915,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-14T01:13:18.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":70921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date."}],"balance_after":89662,"source":{"system":"sec-edgar","filing":"0000899243-22-022286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000089924322022286/doc4.xml","form_type":"4"}},{"id":2235931,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T19:37:51.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":7.06,"expiration_date":"2032-06-08","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-22-014774","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014774/rdgdoc.xml","form_type":"4"}},{"id":2311123,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T21:40:26.000Z","date":"2022-03-14","kind":"other","acquired":true,"shares":4710120,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment is being filed to correct the share holdings reported on the Form 4 filed by the reporting person on March 31, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are managers, to Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary. In exchange for the shares, the reporting person received a promissory note in the principal amount of $36,032,418.00."}],"balance_after":4710120,"source":{"system":"sec-edgar","filing":"0001214659-22-004729","document":"marketforms-55948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922004729/marketforms-55948.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2311122,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T21:40:26.000Z","date":"2022-03-14","kind":"other","acquired":false,"shares":4710120,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are managers, to Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary. In exchange for the shares, the reporting person received a promissory note in the principal amount of $36,032,418.00."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001214659-22-004729","document":"marketforms-55948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922004729/marketforms-55948.xml","form_type":"4/A","original_submission_date":"2022-03-31"}},{"id":2312737,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:27:19.000Z","date":"2022-03-14","kind":"other","acquired":true,"shares":4710121,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares were sold by Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are managers, to Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary.  In exchange for the shares, the reporting person received a promissory note in the principal amount of $36,032,422.83."}],"balance_after":4710121,"source":{"system":"sec-edgar","filing":"0001214659-22-004613","document":"marketforms-55916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922004613/marketforms-55916.xml","form_type":"4"}},{"id":2312736,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:27:19.000Z","date":"2022-03-14","kind":"other","acquired":false,"shares":4710121,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares were sold by Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are managers, to Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary.  In exchange for the shares, the reporting person received a promissory note in the principal amount of $36,032,422.83."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001214659-22-004613","document":"marketforms-55916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922004613/marketforms-55916.xml","form_type":"4"}},{"id":2317636,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T21:50:38.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":1458333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1458333,"derivative":{"exercise_price":9.69,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":1458333},"source":{"system":"sec-edgar","filing":"0001214659-22-004372","document":"marketforms-55853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922004372/marketforms-55853.xml","form_type":"4"}},{"id":2434765,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T17:02:48.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":155039,"price":12.6,"value":1953491.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased by Bellco Legacy LLC at an average price of $12.60 per unit, calculated from the price range of $12.35 to $13.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun."}],"balance_after":195039,"source":{"system":"sec-edgar","filing":"0001214659-22-000701","document":"marketforms-55052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465922000701/marketforms-55052.xml","form_type":"4"}},{"id":2656980,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-24T01:14:07.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":20600,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001209191-21-042879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919121042879/doc4.xml","form_type":"4"}},{"id":2675686,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:47:07.000Z","date":"2021-03-26","kind":"exercise","acquired":false,"shares":3241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-07-27","expiration_date":"2021-07-27","underlying":"Ordinary Shares","underlying_shares":3241},"source":{"system":"sec-edgar","filing":"0001209191-21-039138","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039138/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-22"}},{"id":2675685,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-09T17:47:07.000Z","date":"2021-03-26","kind":"exercise","acquired":true,"shares":3241,"price":5,"value":16205.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021."}],"balance_after":245452,"source":{"system":"sec-edgar","filing":"0001209191-21-039138","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039138/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-22"}},{"id":2675674,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:41:50.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":17.98,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-039131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039131/doc4.xml","form_type":"4"}},{"id":2696747,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-25T12:00:27.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":379066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":18.22,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":379066},"source":{"system":"sec-edgar","filing":"0001214659-21-005878","document":"marketforms-52924.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465921005878/marketforms-52924.xml","form_type":"4"}},{"id":2696746,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T12:00:27.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":379066,"price":18.22,"value":6906582.52,"ownership":{"direct":true},"balance_after":583034,"source":{"system":"sec-edgar","filing":"0001214659-21-005878","document":"marketforms-52924.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465921005878/marketforms-52924.xml","form_type":"4"}},{"id":2742015,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-22T21:19:31.000Z","date":"2021-03-24","kind":"exercise","acquired":false,"shares":3241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-07-27","expiration_date":"2021-07-27","underlying":"Ordinary Shares","underlying_shares":3241},"source":{"system":"sec-edgar","filing":"0001209191-21-027978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121027978/doc4.xml","form_type":"4"}},{"id":2742014,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-22T21:19:31.000Z","date":"2021-03-24","kind":"exercise","acquired":true,"shares":3241,"price":5,"value":16205.0,"ownership":{"direct":true},"balance_after":245452,"source":{"system":"sec-edgar","filing":"0001209191-21-027978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121027978/doc4.xml","form_type":"4"}},{"id":2767845,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T21:00:08.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":199223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":199223,"derivative":{"exercise_price":33.78,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":199223},"source":{"system":"sec-edgar","filing":"0001214659-21-003612","document":"marketforms-52129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465921003612/marketforms-52129.xml","form_type":"4"}},{"id":2767844,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T21:00:08.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":53635,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":203968,"source":{"system":"sec-edgar","filing":"0001214659-21-003612","document":"marketforms-52129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465921003612/marketforms-52129.xml","form_type":"4"}},{"id":3005060,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"price":0,"reported_value":4090015.57,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":0,"derivative":{"exercise_price":16.15,"expiration_date":"2022-02-20","underlying":"Common Stock","underlying_shares":253251},"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005059,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":1304563,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1376313},"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005058,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":650000,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":685750},"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005057,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":228315,"ownership":{"direct":false,"nature":"By Bellco Legacy II Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person currently serves as the trustee of Bellco Legacy II Trust (\"Bellco\"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240872},"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005056,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":173333,"ownership":{"direct":false,"nature":"By Bellco Legacy II Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person currently serves as the trustee of Bellco Legacy II Trust (\"Bellco\"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":182866},"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005055,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":253251,"price":16.15,"value":4090003.65,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":2315314,"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005054,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1376313,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":2062063,"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005053,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":685750,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV Manager LLC is the manager of Vida Ventures, LLC (\"Vida\"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida."}],"balance_after":685750,"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005052,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":240872,"ownership":{"direct":false,"nature":"By Bellco Legacy II Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person currently serves as the trustee of Bellco Legacy II Trust (\"Bellco\"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco."}],"balance_after":679575,"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3005051,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:44:32.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":182866,"ownership":{"direct":false,"nature":"By Bellco Legacy II Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person currently serves as the trustee of Bellco Legacy II Trust (\"Bellco\"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco."}],"balance_after":438703,"source":{"system":"sec-edgar","filing":"0001209191-20-055038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919120055038/doc4.xml","form_type":"4"}},{"id":3114833,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T22:35:22.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":28.24,"expiration_date":"2030-06-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-035676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120035676/doc4.xml","form_type":"4"}},{"id":3121927,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T20:04:51.000Z","date":"2020-06-04","kind":"purchase","acquired":true,"shares":106382,"price":47,"value":4999954.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1798163,"source":{"system":"sec-edgar","filing":"0001214659-20-005383","document":"marketforms-48964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465920005383/marketforms-48964.xml","form_type":"4"}},{"id":3121926,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T20:04:51.000Z","date":"2020-06-04","kind":"purchase","acquired":true,"shares":40000,"price":47,"value":1880000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held in the name of Bellco Legacy LLC (Bellco Legacy).  Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001214659-20-005383","document":"marketforms-48964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465920005383/marketforms-48964.xml","form_type":"4"}},{"id":3199192,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:38:15.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":379066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":379066,"derivative":{"exercise_price":18.22,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":379066},"source":{"system":"sec-edgar","filing":"0001214659-20-002807","document":"marketforms-48389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000121465920002807/marketforms-48389.xml","form_type":"4"}},{"id":3500674,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-05T20:52:36.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of two years."}],"balance_after":10000,"derivative":{"exercise_price":34.83,"expiration_date":"2029-06-02","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-034777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119034777/doc4.xml","form_type":"4"}},{"id":3525808,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T21:10:30.000Z","date":"2019-05-13","kind":"other","acquired":true,"shares":13413,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were received in the pro rata distribution from VVAG described above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":515076,"source":{"system":"sec-edgar","filing":"0001209191-19-030079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119030079/doc4.xml","form_type":"4"}},{"id":3525807,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T21:10:30.000Z","date":"2019-05-13","kind":"other","acquired":false,"shares":598935,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by VVAG, of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":4791480,"source":{"system":"sec-edgar","filing":"0001209191-19-030079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119030079/doc4.xml","form_type":"4"}},{"id":3545400,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-30T23:21:55.000Z","date":"2019-04-26","kind":"other","acquired":true,"shares":13413,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were received in the pro rata distribution from VVAG described above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":501663,"source":{"system":"sec-edgar","filing":"0001209191-19-026675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119026675/doc4.xml","form_type":"4"}},{"id":3545399,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-30T23:21:55.000Z","date":"2019-04-26","kind":"other","acquired":false,"shares":598937,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by VVAG, of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":5390415,"source":{"system":"sec-edgar","filing":"0001209191-19-026675","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119026675/doc4.xml","form_type":"4"}},{"id":3575254,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy","published_at":"2019-03-28T20:52:07.000Z","date":"2019-03-27","kind":"exercise","acquired":false,"shares":128000,"price":4.02,"value":514560.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the stock option vested on each of October 13, 2012, October 13, 2013, October 13, 2014 and October 13, 2015."}],"balance_after":0,"derivative":{"exercise_price":4.02,"expiration_date":"2019-10-14","underlying":"Ordinary Shares","underlying_shares":128000},"source":{"system":"sec-edgar","filing":"0001209191-19-021635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119021635/doc4.xml","form_type":"4"}},{"id":3575253,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-03-28T20:52:07.000Z","date":"2019-03-27","kind":"exercise","acquired":true,"shares":128000,"price":4.02,"value":514560.0,"ownership":{"direct":true},"balance_after":212211,"source":{"system":"sec-edgar","filing":"0001209191-19-021635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119021635/doc4.xml","form_type":"4"}},{"id":3592506,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-15T21:20:31.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":195133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":195133,"derivative":{"exercise_price":26.89,"expiration_date":"2029-03-12","underlying":"Common Stock","underlying_shares":195133},"source":{"system":"sec-edgar","filing":"0001209191-19-019758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119019758/doc4.xml","form_type":"4"}},{"id":3592505,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-15T21:20:31.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":115333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":150333,"source":{"system":"sec-edgar","filing":"0001209191-19-019758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119019758/doc4.xml","form_type":"4"}},{"id":3660050,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-13T22:10:18.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":194445,"price":18,"value":3500010.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was inadvertently omitted from the reporting person's Form 4 filed October 17, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1691781,"source":{"system":"sec-edgar","filing":"0001209191-19-009724","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919119009724/doc4a.xml","form_type":"4/A","original_submission_date":"2018-10-17"}},{"id":3788158,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":285207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1497336},"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788157,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":1140829,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5989352},"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788156,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":27095,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held in the name of the Belldegrun Family Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":142248},"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788155,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":1497336,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1497336,"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788154,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":5989352,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":5989352,"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788153,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":142248,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held in the name of the Belldegrun Family Trust."}],"balance_after":3710006,"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":3788152,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:29:03.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":35000,"price":18,"value":630000.0,"ownership":{"direct":true},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-18-055372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919118055372/doc4.xml","form_type":"4"}},{"id":4190930,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":159700,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"This option provides for 25% vesting on December 27, 2017, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":47.42,"expiration_date":"2026-12-17","underlying":"Common Stock","underlying_shares":159700},"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190929,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":56643,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":56643},"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190928,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":44057,"price":116.13,"value":5116339.41,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":44057},"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190927,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":43500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190926,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":95700,"price":128.04,"value":12253428.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":95700},"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190925,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":500000,"price":180,"value":90000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the Manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190924,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":500000,"price":180,"value":90000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are held in the name of Bioeast, LLC, of which the reporting person is a managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190923,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":430190,"price":180,"value":77434200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities are held in the name of MDRB Partnership, L.P., of which the reporting person is a managing partner. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190922,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":159329,"price":180,"value":28679220.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities are held in the name of The Arie Belldegrun MD, Inc. Profit Sharing Plan, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190921,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1607750,"price":180,"value":289395000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held in the name of Arie and Rebecka Belldegrun as Trustees of the Belldegrun Family Trust dated February 18, 1994."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}},{"id":4190920,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2017-10-06T00:10:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":159160,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 114,950 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a \"Company Restricted Stock Unit\"), held by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000120919117056215/doc4.xml","form_type":"4"}}],"next_cursor":"2017-10-06T00:10:55.000000Z,4190920"}